Pharma — India Trademark Cases
240 decisions indexed
Page 4 of 8 · 240 total
Alkem Laboratories Ltd. v.Eris Health Care Pvt. Ltd. & Ors.
The Delhi High Court addressed a trademark infringement suit filed by Alkem Laboratories against Eris Health Care regarding the alleged misuse of 'GEMCAL' and 'GEMCAL PLUS' trademarks and associated packaging. The court observed that the defendants agreed to change their marks from 'DE-CAL GEM' to 'DECAL PLUS' (and similar changes for 'PLUS'). After reviewing the proposed new artwork, the court allowed the adoption of the revised designs while permanently restraining the defendants from using any mark or packaging deceptively similar to Alkem’s original trademarks and presentation.
Khandelwal Laboratories P Ltd v.Nava Healthcare P Ltd
The Delhi High Court formally recorded an amicable settlement between Khandelwal Laboratories P Ltd and Nava Healthcare P Ltd regarding trademark infringement. The Defendant, Nava Healthcare, acknowledged the Plaintiff's exclusive rights in 'KHANDELWAL' and 'KLAB' logos used for pharmaceutical products. As part of the settlement, the Defendant agreed to a permanent injunction, ceased using the marks, committed to disposing of existing stock by specific deadlines, and agreed to pay outstanding liabilities totaling over Rs 1.51 crores.
Mankind Pharma Limited v.Nisekind Pharma Private Limited
The Delhi High Court granted an ex-parte ad interim injunction in favor of Mankind Pharma Limited against Nisekind Pharma Private Limited. The court found that Mankind, a major player in the Indian pharmaceutical industry, had established a prima facie case regarding trademark infringement. The ruling specifically restrained the defendant from using the name 'NISEKIND PHARMA PRIVATE LIMITED' and any similar mark containing the word element KIND for medicinal preparations, citing potential consumer confusion and dilution of Mankind's well-known marks.
Surge Biotech Pvt Ltd v.Surge Pharmaceuticals Pvt Ltd
The Gujarat High Court disposed of an Appeal from Order in a trademark dispute between Surge Biotech Pvt Ltd and Surge Pharmaceuticals Pvt Ltd. Due to mutual consensus between both parties, the court quashed the previous order passed by the trial court regarding Exh.5 application. The case has been remanded back to the trial court to decide the matter afresh, ensuring both sides are given an opportunity to present their arguments.
Lyka Labs Limited v.Lyka Biotech Private Limited
The petitioner, Lyka Labs Limited, filed an Interim Application against Lyka Biotech Private Limited for infringement of its trademark 'LYKA' and passing off. The court accepted the defendant's statement that it had discontinued using the impugned mark and domain name. Consequently, the court passed a temporary injunction restraining the respondent from using similar marks in relation to pharmaceutical products.
Himalaya Wellness Company & Ors. v.Elder Labs Limited & Anr.
The dispute between Himalaya Wellness Company and Elder Labs Limited was resolved through mediation, leading to a comprehensive settlement agreement accepted by the Delhi High Court. The defendants acknowledged the plaintiffs' rights in trademarks like 'Liv.52' and 'HIMALAYA', as well as their trade dress (orange and green color combination). In exchange for discontinuing infringing activities and paying damages of Rs. 3,00,000/-, the suit was decreed based on the settlement terms.
M/S Esme Consumer Private Limited v.M/S Prass Naturaceutical Pvt Ltd
The Delhi High Court granted an interim injunction in favor of M/S Esme Consumer Private Limited against M/S Prass Naturaceutical Pvt Ltd. The court found that the defendant's adoption of the mark 'NATURASSENCE' was closely identical and deceptively similar to the plaintiff's registered trademarks, including 'NATURE'S ESSENCE'. Given the prima facie case made by the plaintiff regarding goodwill and reputation, the court restrained the defendant from using any confusingly similar marks or trade dress until further hearing.
Dr Ashim Kumar Biswas v.A To Z Pharmaceuticals And Laboratory & Anr.
The Delhi High Court granted an interim injunction in favor of Dr. Ashim Kumar Biswas against A To Z Pharmaceuticals for trademark infringement and passing off. The court found that the defendant's product was an exact copy of the plaintiff's Ayurvedic medicine, using a deceptively similar mark ('DR. BISWASH') while also naming the plaintiff as the manufacturer. Given the clear prima facie case, balance of convenience, and risk of irreparable harm to the plaintiff's reputation, the court restrained the defendants from continuing the infringing activities until further hearing.
Hamdard National Foundation (India) v.Sadar Laboratories Pvt. Limited
The Delhi High Court dismissed the plaintiffs' application for an ad interim injunction against Sadar Laboratories, which was seeking protection for its well-known trademark 'Rooh Afza'. The court found that while 'Rooh Afza' may be a strong mark, the defendant's use of 'Dil Afza' did not necessarily cause consumer confusion, especially given the long history and peaceful co-existence of similar marks in the pharmaceutical market. However, the defendant was directed to maintain detailed sales accounts during the pendency of the suit.
GLAXO GROUP LIMITED v.CIAN HEALTHCARE LIMITED
The Delhi High Court formally decreed the suit between Glaxo Group Limited and Cian Healthcare Limited based on a settlement agreement reached through mediation. The defendant agreed to pay Rs. 1,50,000 towards the plaintiff's claim and costs, and crucially, consented not to use the trademark 'BETASOL' for their products. This resolution allowed both parties to conclude the litigation amicably.
Allergan, Inc. v.The Registrar Of Trade Marks
Allergan, Inc. challenged the Registrar of Trade Marks' refusal to register its trademark in the Delhi High Court. The court initiated proceedings by issuing notice to the Registrar, allowing the defendant two weeks to file a response. This order sets the stage for a substantive hearing on whether Allergan meets the criteria for trademark registration.
Toasha Agencies And Another v.Siddhant Choudharyand Anr.
The Delhi High Court framed a comprehensive set of issues in the trademark passing-off suit filed by Toasha Agencies against Siddhant Choudhary and others. The core disputes revolve around whether the plaintiffs are lawful proprietors of the 'TOASHA' trade name, if they possess distinctive goodwill, and crucially, whether the defendants have engaged in passing off or unfair competition. The court directed both parties to file their lists of witnesses and evidence, setting the stage for a full trial.
Sun Pharmaeutical Industries Limited v.Indkus Nexa
Sun Pharmaeutical Industries Limited filed a civil suit against Indkus Nexa and Indo Himalaiyan Herbs Inc. alleging infringement of its registered trademark VOLINI, copyright violation in its packaging art, and passing off due to the use of 'VOLINEX'. The plaintiff sought permanent injunctions and damages. Ultimately, the dispute was resolved through a memorandum of compromise signed by both parties.
Sun Pharmaeutical Industries Limited v.Indkus Nexa
Sun Pharmaeutical Industries Limited filed a civil suit against Indkus Nexa and Indo Himalaiyan Herbs Inc. alleging trademark infringement, copyright violation, and passing off concerning its registered mark 'VOLINI'. The plaintiff sought permanent injunctions to stop the use of similar marks like 'VOLINEX' and imitation packaging. The dispute was ultimately resolved through a memorandum of compromise signed by both parties.
Himalaya Wellness Company & Ors. v.Abony Healthcare Limited Through Its Directors & Anr.
The Delhi High Court granted an ex-parte ad interim injunction in favor of Himalaya Wellness Company against Abony Healthcare Limited. The suit alleged trademark infringement, passing off, trade dress infringement, and copyright violation concerning the 'Liv' product line. The court found prima facie evidence of deceptive similarity based on identical packaging elements, color schemes (orange/green), and similar product names ('Liv.52' vs 'Liv.55 DS'). This interim order prevents the defendants from continuing their alleged infringing activities pending the final hearing.
Macleods Pharmaceuticals Limited v.M/S Skynet Placements & Ors.
The Delhi High Court granted an ad-interim injunction in favor of Macleods Pharmaceuticals Limited against M/S Skynet Placements & Ors. The court found a prima facie case that the defendants were using the plaintiff's registered trademark 'MACLEODS' for deceptive purposes, specifically related to fake job offers. Consequently, the defendants were restrained from promoting or offering services under the mark, and banks were directed to freeze specific accounts linked to the alleged fraudulent activity.
Emami Ltd. v.Torque Pharmaceuticals Pvt. Ltd.
Emami Ltd. vs Torque Pharmaceuticals Pvt. Ltd. saw its multi-faceted IP litigation reach a conclusion through settlement in the Calcutta High Court. The original suit, which involved claims of infringement across trademark, copyright, design, and passing off, was formally withdrawn by both parties. The court accepted the Terms of Settlement, decreeing the parent suit and disposing of all connected applications. This resolution allows both companies to move forward without further legal entanglement.
Dr.Reddys Laboratories Limited v.West-Coast Pharmaceutical Works Ltd.
In this trademark infringement suit concerning Omeprazole capsules, the Delhi High Court addressed a request for ex parte ad interim relief. While the plaintiff presented an arguable case regarding the deceptive similarity between 'OMEZ' and 'OMES', the court ultimately refused immediate injunction. The judge emphasized that mere prima facie evidence is insufficient; the balance of convenience, irreparable loss, and public interest must be weighed, leading to a decision to allow the defendant a chance to respond.
Alkem Laboratories Ltd. v.Nava Healthcare Pvt. Ltd. & Ors.
In this trademark infringement suit concerning pharmaceutical products, the Delhi High Court addressed the plaintiff's request for immediate interim injunction. The court declined to grant an ex parte order, emphasizing that the defendants had claimed prior use of the mark since 2018 and that public interest required them to be given a chance to respond. Consequently, notice was issued to the defendants, allowing the litigation process to proceed with due consideration for all parties.
Dharmendra Kumar Aggarwal v.Govt. Of Nct Of Delhi Through The Secretary & Anr.
This petition addressed the critical issue of supply and availability of the drug Tocilizumab 400 MG (Actemra) for COVID-19 patients in Delhi. The court examined submissions from Roche India, which indicated that global demand far exceeded current manufacturing capabilities. While Roche mentioned partnerships with other entities to meet demand, they provided no clear assurance regarding further supply to India. Consequently, the court issued detailed directions to both Roche and the Union of India to provide comprehensive affidavits on supply chain status, patent details, and potential alternatives.
Centaur Pharmaceuticals Pvt Ltd v.Mhs Pharmaceuticals Pvt Ltd
Centaur Pharmaceuticals filed an Interim Application against MHS Pharmaceuticals. The court noted that the dispute was complex and did not meet the criteria for an immediate ad-interim order, requiring a final hearing after both parties submitted additional evidence.
Cutis Biotech Thr.Its Sole Prop. v.Serum Institute of India Private
This Bombay High Court appeal addressed a dispute over the trademark 'Covishield' between Cutis Biotech and Serum Institute of India. Although both parties had pending applications for the mark, Cutis Biotech sought an interim injunction based on passing off. The court ultimately dismissed the appeal, finding that the balance of convenience did not favor the appellant, especially given the critical public health role of the 'Covishield' vaccine in ongoing vaccination drives.
The Himalaya Drug Company & Ors v.Ashok Kumar & Ors
The Delhi High Court issued interim protective orders in favor of The Himalaya Drug Company against Ashok Kumar & Ors regarding trademark infringement. The court restrained the defendants from using Himalaya's registered logos, trademarks (including 'Himalaya Pure Herbs'), specific domain names like <himalayawelness.com>, and associated email IDs. Furthermore, the court directed the freezing of certain websites and domain names to prevent further unauthorized capitalization on the plaintiff's goodwill.
Franco-Indian Pharmaceuticals Pvt Ltd v.Nutramarck Lifesciences Pvt Ltd
This interim application sought relief concerning the alleged infringement of a trademark (STIMULIV) by the defendant (Nutramarck Lifesciences Pvt Ltd), which was using the mark IMMULIV. The defendant, through its director, provided assurances that they would cease manufacturing and using the impugned marks.
Franco-Indian Pharmaceuticals Pvt Ltd v.Nutramarck Lifesciences Pvt Ltd
This interim application was filed regarding a trademark dispute between Franco-Indian Pharmaceuticals Pvt Ltd and Nutramarck Lifesciences Pvt Ltd. The defendant, through its director Mr Abhinav, stated that they had stopped manufacturing products with the impugned mark IMMULIV and would remove them from e-commerce websites within two weeks.
M/S Nutrica Pusti Healthcare Pvt. Ltd. v.M/S Morepen Laboratories Ltd.
The Delhi High Court dismissed the appeal filed by Nutrica Pusti Healthcare Pvt. Ltd., upholding the Commercial Court's interim injunction against Morepen Laboratories Ltd. The court found that the marks used by the appellants were deceptively similar to those of the respondents, particularly considering the pharmaceutical context and potential for consumer confusion. This judgment reinforces the strict application of trademark principles in the highly regulated pharma sector.
Fdc Limited v.Shripal Mangalchand Jain
Fdc Limited filed a Commercial IP Suit against Shripal Mangalchand Jain regarding trademark infringement. The dispute centers on FDC's mark PYRIMON (used for anti-bacterial isolation) versus the Defendant's mark PRIMON-N (used for birth control pills and menopausal hormone therapy).
Laboratories Griffon Pvt Ltd v.Ramesht Industry Pvt Ltd
The Plaintiffs, Laboratories Griffon Pvt Ltd, filed a suit alleging trade mark infringement and passing off against the Defendants, Ramesht Industry Pvt Ltd. The dispute centers on the use of identical or confusingly similar marks (GLIMET, GLIMET-1, GLIMET-2) for pharmaceutical products used in treating diabetes. The Court found a prima facie case and granted an ad-interim injunction.
Centaur Pharmaceuticals Pvt Ltd v.Mhs Pharmaceuticals Pvt Ltd
Centaur Pharmaceuticals filed a Leave Petition against MHS Pharmaceuticals regarding the alleged infringement of its long-standing pharmaceutical trademark, SINAREST, by the Defendant's mark, SINARITE. The court granted the leave petition and directed both parties to file affidavits in reply and rejoinder within specified timelines.
Emami Ltd v.Torque Pharmaceuticals Pvt. Ltd.
The defendant filed an application seeking modification of a previous interim order. The court observed that the suit involved infringement and passing off and was valued in excess of the specified limit. Consequently, the case (IN EOS/4/2020) and the associated application (IA GA 1 of 2021) were transferred to the Commercial Division.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.